Miguel Martin, MD, PhD

home / authors / miguel-martin-md-phd

Articles

21 Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) as Adjuvant Treatment in Patients (pts) With HR+/HER2– Early Breast Cancer (EBC): Final Invasive Disease-Free Survival (iDFS) Analysis From the NATALEE Trial

21 Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) as Adjuvant Treatment in Patients (pts) With HR+/HER2– Early Breast Cancer (EBC): Final Invasive Disease-Free Survival (iDFS) Analysis From the NATALEE Trial

Gabriel N. Hortobagyi, MD, FACP;Daniil Stroyakovskiy;Denise A. Yardley, MD;Chiun-Sheng Huang;Peter A. Fasching;John Crown;Aditya Bardia, MD, MPH;Stephen Chia;Seock-Ah Im;Miguel Martin, MD, PhD;Sherene Loi, MD, PhD;Binghe Xu;Sara A. Hurvitz, MD;Carlos Barrios;Michael Untch, MD, PhD;Rebecca Moroose;Frances Visco;Federico Parnizari;Farhat Ghaznawi;Zheng Li;Sorcha Waters;Arunava Chakravartty;Dennis J. Slamon, MD, PhD
August 7th 2024
31 Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2–, High-Risk Early Breast Cancer: Results From a Preplanned MonarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

31 Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2–, High-Risk Early Breast Cancer: Results From a Preplanned MonarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

Hope S. Rugo, MD;Nadia Harbeck, MD, PhD;Priya Rastogi, MD;Joyce O’Shaughnessy, MD;Frances Boyle;Javier Cortés, MD;Matthew P. Goetz, MD;Erika P. Hamilton, MD;Chiun-Sheng Huang;Elżbieta Senkus;Alexey Tryakin;Patrick Neven, MD, PhD;Jens Huober, MD;Ran Wei;Valérie André;Maria Munoz;Belen San Antonio;Ashwin Shahir;Miguel Martin, MD, PhD;Stephen Johnston
July 9th 2024
Site Logo

Paclitaxel Plus Vinorelbine in Metastatic Breast Ca Patients With Contraindications to Receive Anthracyclines

Miguel Martin, MD, PhD;Ana Lluch, MD;Javier Garcia-Conde, MD
January 1st 1998

Thirty-three metastatic breast cancer patients with prior chemotherapy (adjuvant alone, 9 patients; chemotherapy for metastatic disease alone, 13 patients; chemotherapy for both, 11 patients) received paclitaxel (Taxol) 135

Site Logo

UFT/Methotrexate/Leucovorin for Breast Cancer Patients in Progression After HDCT/PBPC Support

Miguel Martin, MD, PhD;Antonio Casado, MD;José Antonio López-Martin, MD;Alvaro Rodriguez-lescure, MD;Yago Nieto, MD;Francisco Ayala, MD;Eduardo Diaz-rubio, MD, PhD
September 2nd 1997

Twenty-four patients with metastatic breast cancer that had progressed after high-dose chemotherapy with peripheral blood progenitor cell (PBPC) support were given intramuscular methotrexate in combination with oral

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Breast Induration in 42-Year-Old Patient
Published: April 12th 2016 | Updated: July 16th 2025
Breast Induration in 42-Year-Old Patient